Bleeding Disorder Testing Market Forecasts to 2028 – Global Analysis By Product (Reagents, Consumables, Instruments and Other Products), Drug Class (Fibrin Sealants, Desmopressin Acetate, Antifibrinolytics, Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates and Other Drug Classes), Treatment, Indication, End User and By Geography
According to Stratistics MRC, the Global Bleeding Disorder Testing Market is accounted for $88.5 million in 2022 and is expected to reach $155.08 million by 2028 growing at a CAGR of 9.7% during the forecast period. Bleeding disorders occur when the body's ability to clot blood is impaired. A clot forms on the infected body part, which is made up of platelets and a specific type of blood cell. This clot prevents germs from entering the blood and also prevents blood from draining from the injured area. Bleeding disorder testing can help determine whether certain clotting factors are involved and measures how long it takes blood to clot. The test evaluates how long it takes the vessels cut to constrict and how long it takes for platelets in the blood to seal off the hole.
According to the National Hemophilia Foundation, Von Willebrand disease is the most common bleeding disorder affecting approximately 1 in every 100 people or up to 1% of the U.S population.
Market Dynamics:
Driver:
The rise in the blood related disorders
Blood related disorders are chronic illness. They are also life threatening as they circulate throughout the blood. Disorders such as liver disorders, anaemia, and other blood coagulation disorders increased and raised the demand for bleeding disorders treatment. These inherited disorders brought lucrative growth in the market.
Restraint:
Scarcity of skilled professionals
The scarcity of skilled professionals and trained expertise will be a major impediment to the growth of the bleeding disorders treatment market. Medication costs will also slow the market's growth rate. Inadequate reimbursement policies will also limit the scope. Unprofessional treatments can cause major impact on the patient’s health. This challenge is hindering the growth of the market.
Opportunity:
Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influences the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market and fueling the market growth.
Threat:
Low adherence to guidelines
The lower focus of the national organizations and other institutions in emerging countries towards increasing the awareness regarding these conditions resulting in the low penetration of testing. This challenge is limiting the early diagnosis and proper care of patients which is hindering the market growth.
Covid-19 Impact
The COVID-19 pandemic has had a major long-term positive impact on the bleeding disorders treatment market. Initially, there was a drop in the market as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased exponentially and made the market to sustain.
The product segment is expected to be the largest during the forecast period
The product segment is estimated to have a lucrative growth, due to developing healthcare infrastructure and healthcare access. The rising awareness regarding the disorders are leading to increased demand. Advancements in technology are improving automation and portable analyzers are anticipated to the growth of the market.
The hospital segment is expected to have the highest CAGR during the forecast period
The hospital segment is anticipated to witness the fastest CAGR growth during the forecast period, due to rising technology treatment of the disorders. The hospitals rate is increasing due to the severity of these disorders which is leading to an increased demand of testing instruments and reagents in hospitals and clinics which is propelling the market growth.
Region with highest share:
Europe is projected to hold the largest market share during the forecast period owing to the growing prevalence of disorders in the region. The rising faithfulness to guidelines and the growing patient population increased the demand. The testing instruments and devices are very advanced in this region which propelled the market share.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period, owing to the growing launch of testing instruments and the escalating number of regulatory approvals. The increasing awareness and diagnosis rate of bleeding disorder has anticipated to fuel the market growth.
Key players in the market
Some of the key players profiled in the Bleeding Disorder Testing Market include Sysmex Corporation, Siemens Healthcare GmbH, Alexion Pharmaceuticals, Abbott, Amgen Inc, F. Hoffmann-La Roche Ltd, Biogen Inc, Alnylam Pharmaceuticals Inc, Pfizer Inc, HORIBA Ltd, Bayer AG, Xenetic Biosciences Inc, Thermo Fisher Scientific Inc, CSL Behring, Sanofi S.A, Catalyst Biosciences, Grifols, S.A, Octapharma Plasma, Inc, Bristol-Myers Squibb, Johnson & Johnson, Sun Pharma Industries Limited, Kedrion Biopharma Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, Dimension Therapeutics Inc, Novo Nordisk A/S, Ferring Pharmaceuticals
Key Developments:
In March 2021, F. Hoffmann La Roche Ltd, launched 8 new configurations for Cobas pro integrated solutions with an aim to maximize throughput and increase testing efficiency.
In Feb 2020, Novo Nordisk A/S launched Esperoct, an anti-hemophilic factor, in the United States in February 2020 for the treatment of adults and children with haemophilia A, i.e., to reduce and control bleeding episodes even during surgery.
Products Covered:
• Reagents
• Consumables
• Instruments
• Other Products
Drug Classes Covered:
• Fibrin Sealants
• Desmopressin Acetate
• Antifibrinolytics
• Plasma Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Other Drug Classes
Treatments Covered:
• Hormone Replacement Therapy
• Contraceptives
• Clot Stabilizing Drugs
• Desmopressin
• Fibrin Sealants
• Pipeline Analysis
• Drugs Applied To Cuts
• Other Treatments
Indications Covered:
• Von Willebrand Disease
• Hemophilia A
• Hemophilia B
• Other Indications
End Users Covered:
• Research Institutes
• Hospital
• Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook